Pipeline
KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance a second generation of orally delivered small molecules that demonstrate high blood-brain-barrier penetration, selective kinase inhibition, and enhanced clearance of toxic protein buildup associated with neurodegenerative disease. Additionally, selective inhibition of kinases related to mast cell-mediated inflammatory conditions has the potential to reduce symptoms for patients suffering from immune conditions.
Discovery
Ph 1
IND-Enabling
Candidate
Target(s)
Pre-clinical
Alzheimer's disease
KFRX03
c-ABL, c-KIT, FYN
Amyotrophic lateral sclerosis (ALS)
KFRX04
c-KIT, PIKFYVE
Frontotemporal dementia
Parkinson's disease (LRRK2 mutant)
KFRX06
c-KIT (mutants)
Parkinson's disease & dementia (PDD)
Mast cell activation syndrome (MCAS)
Urticaria
KFRX05
c-KIT (mutants), LRRK2
KFRX03
Alzheimer's Disease
Target(s) : c-ABL, c-KIT, FYN
Discovery
Pre-clinical
IND-Enabling
Ph 1
KFRX04
Target(s) : c-KIT, PIKFYVE
KFRX05
Amyotrophic lateral sclerosis (ALS)
Mast Cell Activated Syndrome (MCAS)
Urticaria
Target(s) : c-KIT (mutants), LRRK2
Parkinson's Disease & Dementia (PDD)
KFRX06
Parkinson's disease (LRRK2 mutant)
Target(s) : c-KIT (mutants)
Frontotemporal dementia